Avadel Pharmaceuticals — Investor Presentation (February 2018)
29 slides from Avadel Pharmaceuticals's investor presentation, Feb 13, 2018
Slide 1: Avadel Pharmaceuticals plc Corporate Presentation
Avadel Pharmaceuticals pic Corporate Presentation
Slide 2: Safe Harbor
Safe Harbor \ Avadel ‘This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 41933 and Section 21€ of the Securities Exchange Act of 1934. The words “will” “may” “believe,” “expect,” “anticipate, “estimate,” “project” and similar expressio
Slide 3: Integrity
Integrity + Results oriented + Highest ethical standards + Leadership + aligned ‘Supportive Senda of ingen) + Accountable + Passionate/driven + Communication + Patient-focused + Quality without + Flexible/Agile
Slide 4: Transition to Specialty Pharma
a, Transition to Specialty Pharma Ny Avadel — Key Dates: 1990 ~ Flamel Technologies SA est. in Lyon, France with focus on drug delivery & reformulation for large pharma 2012 ~ Acquired Eclat Pharmaceuticals — transitioned from drug delivery to specialty pharma model 2013-2016 - FDA approved 3 UMD pr
Slide 5: Recent Highlights
Betent Highlights. YrAvadel Profitable base business for 2017 + Operating cash flow of $30 million nine months ended September 30, 2017 $115 million in cash & marketable securities at September 30, 2017 REST-ON Phase Il! trial for FT218 + Orphan Drug Designation for FT 218 Noctiva™ License Acquisiti
Slide 6: First & Only FDA-Approved Treatment for Nocturia due to Nocturnal Polyuria
First & Only FDA-Approved Treatment for Nocturia due to Nocturnal Polyuria
Slide 7: Noctiva: Issues & Opportunities
Noctiva™: Issues & Opportunities * Nocturia due to nocturnal polyuria causes patients to awaken 2 or more times / night to urinate + Nocturia is an under-recognized condition with substantive consequences, morbidities & diminished quality of life*2 + Inclinical practice, nocturia is often treated in
Slide 8: Noctiva: Overview
Noctiva™: Overview Avadel + Noctiva™ is a proprietary, low-dose, intranasal formulation of Wa desmopressin acetate, a synthetic analogue of anti-diuretic hormone, ~ vasopressin + Past formulations of desmopressin unable to reliably control anti- diuretic effect beyond hours of sleep, creating risk o
Slide 9: Noctiva: Clinical Development
Avadel Noctiva™: Clinical Development* —= * Over 2,300 patients evaluated in clinical studies Noctiva * Two randomized pivotal trials of 1,045 patients { + Statistical efficacy in terms of nocturie episodes & inn acces greater reduction in nocturi¢ episodes . . Average reduction of nocture épisodes
Slide 10: Nocturia: Prevalence in Men & Women
Nocturia: Prevalence in Men & Women YAvadel Women . — teenie om = widsight " - nee me, — Sora ed . g ee Lf», g g wo. iT aie 4 ge SZ je é fo =“ 2g é = VE sl y ry cy eo. Age (years) Prevalent condition in both men & women — increases with age
Slide 11: Nocturia: Nocturnal Polyuria in Majority of Patients
Nocturia: Nocturnal Polyuria in Majority of Patients Avadel Europe? Japan? USA? n=845 n=41* n=934 Ene Bl without np
Slide 12: Nocturia: Falls in Elderly Patients
5, Nocturia: Falls in Elderly Patients \ Avadel = + Primary outcome: 1-year cumulative incidence of falls with moderate/severe vs mild lower urinary tract symptoms (LUTS) at baseline* * Nocturia was among the LUTS most strongly associated with falls* 2-3 Episodes/Night 4-5 Episodes/Night % % RR® (95
Slide 13: Nocturia: Mortality
Nocturia: Mortality *Avadel Women ‘Survival Probability / : 8 ‘Survival Probability x Noctua 25 | Peete <2 — noctiia 2+ 0 12 % % 48 co 72 e oo Toa im 21m 0 12 & % 4 co 72 e oo va 1m 121m Months Months 22 voids/night associated with worse survival
Slide 14: Nocturia: Market Overview
Avadel Nocturia: Market Overvi Prevalence rate: 16%" ~50% Dx nocturia alone ~50% Dx nocturia with Diagnosis rate: 27%25 other (OAB/BPH) 6 to 12 million® annual TRxs Treatment rate: 27%°7 $28+* current annual market value roe iyo tat Ret
Slide 15: Revenue Opportunity
Revenue Opportunity Avadel peok revenue opportunity Assumes penetration of curently treated pool at peak Expanded launch opportunity revenue opportunity Assumes 11% penetration and % growth in the treated patient pool ak
Slide 16: Hospital Products
Hospital Products ; Avadel First to gain FDA approval for neostigmine, ephedrine and full-line phenylephrine 2006 FDA announced Marketed Unapproved Drugs ~ Compliance Policy Guide: + Receive NDA approval — FDA will remove competing unapproved products until generic entry 2013 — 2016 Avadel received
Slide 17: Micropump / LiquiTime
Micropump® LiquiTime™
Slide 18: Micropump Overview
Micropump® Overview Avadel Microparticulate system that allows the development of modified and/or controlled release of solid, oral dosage formulations of drugs Micropump" Granules: ~ Drug granulate or layered neutral core ~ Polymer coating © Consste of multinle-dove system containing from '5,000- 5
Slide 19: LiquiTime Overview
LiquiTime™ Overview : Avadel Potential / Intended for development of modified/controlled release liquid formulations for patients having issues _ swallowing tablets/capsules + Not limited to working solely with ionic drugs as with resin- complex based technologies + Easy-to-swallow, good mouthfeel,
Slide 20: Slide 20
Slide 21: Narcolepsy Overview
Narcolepsy Overview *Avadel Asleep disorder, involving irregular patterns in Rapid Eye Movement (REM) sleep and significant disruptions of normal sleep/wake cycle > on rcolepsy ~ -Estimated~ 200,000 - Only 25% of people -13,000 diagnosed patients - Xyrem® 2017 Revenue ‘Americans suffer from With nar
Slide 22: FT218: Potential for Improved Treatment
FT218: Potential for Improved Treatment *Avadel FT218: Once-nightly formulation of sodium oxybate utilizing Avadel’s proprietary extended-release Micropump® technology Studied in 40 healthy volunteers’ v ‘Comparable AUC as Xyrem® on dose- for-dose basis / Similar onset of action to Xyrem® Similar bl
Slide 23: REST-ON Phase III Trial
REST-ON Phase III Trial — Avadel Double-Blind, Randomized, Placebo-Controlled, Study to Assess Safety and Efficacy of Once Nightly Sodium Oxybate (FT218) for the Treatment of Excessive Daytime Sleepiness (EDS) and Cataplexy in Patients with Narcolepsy 264 Patients, ages 16 + 55 clinical sites across
Slide 24: Intellectual Property
Intellectual Property Avadel | Product. u | roduc June 2030 September 2025 October 2022 April 2023 April 2023
Slide 25: GAAP Financial Results
GAAP Financial Results YrAvadel — (a $000s, except for per share amounts) ‘eae Hed Deemer ‘Nine Months Ended September Prades and svi sunz sis sisn09 stows eens and aca evense sot m1 270 st 2305 Tot eves Tee206 Tra90s Tass Operating pense: Cont ofpmduct and series sl ped naw a0 ms Research and devel
Slide 26: Cash Flow Summary
Cash Flow Summary Avadel — (Gn $000"s) [Nine Months Ended September 30, ‘Total Cash and Marketable Securities 2017 2016 Beginning Balance 154,195 144.802 ‘Operating Cash Flows (exel tax and earnout payments) 73.258 49,636 EarnoutRoyalty Payments (29.136) (24227) lncome Taxes (14,605) (2.200) ‘Acquis
Slide 27: Appendix
Appendix
Slide 28: Noctiva Boxed Warning
«Avadel Noctiva™ (desmopressin acetate) Boxed Warning ‘WARNING: HYPONATREMIA NOCTIVA can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest or death, NOCTIVA is contraindicated in patients at increased rsk of severe hyponatremia, such as pa
Slide 29: Product & Safety Information
ua Product & Safety Information »y Avadel Please click below or visit our websites for full prescribing and safety information for our marketed products Bloxiverz™ https://www.avadel.com/products/hospital/bloxiverz-reg-/ Vazculep ™ https://www.avadel.com/products/hospital/vazculep-reg-/ Akovaz ™ htt
Avadel Pharmaceuticals — Investor Presentation (February 2018) on 6ix